ADC Therapeutics SA (ADCT:NYSE) closed at $1.51 on October 26, 2026, up 4.51% on the day. The stock trades 69.8% below its 52-week high of $4.98 and 92.9% above its 52-week low of $0.780. Over the past year, it lost 64.8%. ADC Therapeutics SA is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, ADCT closed higher on 113 days (45%). Its best day was December 10, 2025 (+13.60%) and its worst was June 4, 2026 (-57.14%). The stock moved 10% or more in a single session 16 times. It opened at least 5% above the previous day's high 1 time.
ADC Therapeutics SA is a United States-based clinical-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ADCT-402, ADCT-301, ADCT-602, and ADCT-601.
Find more stocks like ADCT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.